Biocon Claims Edge For Adalimumab In US
Cites Encouraging Payer Discussions Over Humira Biosimilar
Biocon, which is set to close its deal with Viatris shortly, says it is in a “very good position” to vie for a share of the adalimumab biosimilar pie in the US and has had encouraging preliminary discussions with payers.
